Subcortical Myoclonus and Associated Dystonia in 22q11.2 Deletion Syndrome
By: Vincent Van Iseghem, Eavan McGovern, Emmanuelle Apartis, Boris Keren, Marie Vidailhet, Emmanuel Roze and Bertrand Degos
Open Access
|Jan 2020References
- 1McDonald-McGinnDM, SullivanKE, MarinoB, PhilipN, SwillenA, VorstmanJAS, et al. 22q11.2 deletion syndrome. Nat Rev Dis Prim 2015;1:15071. doi: 10.1038/nrdp.2015.7127189754
- 2DufournetB, NguyenK, CharlesP, GrabliD, JacquetteA, BorgM, et al. Parkinson’s disease associated with 22q11.2 deletion: clinical characteristics and response to treatment. Rev Neurol (Paris) 2017;173(6):406–410. doi: 10.1016/j.neurol.2017.03.02128461026
- 3BootE, ButcherNJ, van AmelsvoortTA, LangAE, MarrasC, PondalM, et al. Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. Am J Med Genet Part A 2015;167(3):639–645. doi: 10.1002/ajmg.a.36928
- 4BaralleD Myoclonic movement disorder associated with microdeletion of chromosome 22q11. J Neurol Neurosurg Psychiatry 2002;73(5):600–601. doi: 10.1136/jnnp.73.5.60012397165
- 5CavinessJN, BrownP Myoclonus: current concepts and recent advances. Lancet Neurol 2004;3(10):598–607. doi: 10.1016/S1474-4422(04)00880-415380156
- 6BootE, BassettAS, MarrasC 22q11.2 Deletion syndrome-associated Parkinson’s disease. Mov Disord Clin Pract 2019;6(1):11–16. doi: 10.1002/mdc3.1268730746410
- 7StrehlowV, SwinkelsMEM, ThomasRH, RappsN, SyrbeS, DornT, et al. Generalized epilepsy and myoclonic seizures in 22q11.2 deletion syndrome. Mol Syndromol 2016;7(4):239–246. doi: 10.1159/00044844527781034
- 8LemkeJR, Beck-WödlS, ZanklA, RiegelM, KrämerG, DornT Juvenile myoclonic epilepsy with photosensitivity in a female with velocardiofacial syndrome (del(22)(q11.2)) – causal relationship or coincidence? Seizure 2009;18(9):660–663. doi: 10.1016/J.SEIZURE.2009.07.00819695908
- 9BootE, BooijJ, AbelingN, MeijerJ, da Silva AlvesF, ZinkstokJ, et al. Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia – relationship with COMT Val108/158 Met polymorphism, gender and symptomatology. J Psychopharmacol 2011;25(7):888–895. doi: 10.1177/026988111140064421447540
- 10BootE, BooijJ, ZinkstokJ, AbelingN, De HaanL, BaasF, et al. Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. Neuropsychopharmacology 2008;33:1252–1258. doi: 10.1038/sj.npp.130150817653112
- 11ButcherNJ, MarrasC, PondalM, RusjanP, BootE, ChristopherL, et al. Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson’s disease. Brain 2017;140(5):1371–1383. doi: 10.1093/brain/awx05328369257
- 12LagardeJ, RozeE, ApartisE, PothalilD, SedelF, CouvertP, et al. Myoclonus and dystonia in cerebrotendinous xanthomatosis. Mov Disord 2012;27(14):1805–1810. doi: 10.1002/mds.2520623115103
DOI: https://doi.org/10.5334/tohm.532 | Journal eISSN: 2160-8288
Language: English
Submitted on: Sep 18, 2019
Accepted on: Dec 5, 2019
Published on: Jan 24, 2020
Published by: Columbia University Libraries/Information Services
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2020 Vincent Van Iseghem, Eavan McGovern, Emmanuelle Apartis, Boris Keren, Marie Vidailhet, Emmanuel Roze, Bertrand Degos, published by Columbia University Libraries/Information Services
This work is licensed under the Creative Commons License.